<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02602847</url>
  </required_header>
  <id_info>
    <org_study_id>2012.720</org_study_id>
    <nct_id>NCT02602847</nct_id>
  </id_info>
  <brief_title>Study of Covalently Closed Circular DNA (cccDNA) in Liver Transplant Patients With B Virus Markers</brief_title>
  <acronym>ECOGREFFE-B</acronym>
  <official_title>Study of cccDNA in Liver Transplant Patients With B Virus Markers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to validate in the context of liver transplantation, the interest of
      the cccDNA assay technique developed by the team of Professor Zoulim (INSERM U1052) on liver
      biopsy and correlate this assay cccDNA in hepatitis B virus (HBV) viral load and serum liver
      through several groups of patients at transplantation (on graft and native liver explant) and
      after transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">November 2018</completion_date>
  <primary_completion_date type="Actual">November 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>cccDNA rate on native explant and liver transplant during transplantation and on liver biopsy</measure>
    <time_frame>1 year after transplantation</time_frame>
    <description>cccDNA rate will be assessed on native explant and liver transplant during transplantation and on liver biopsy (between M1 to M3 and 12 months (M12) after transplantation) to study the colonization of new hepatocytes by HBV</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between cccDNA rate and serologic status</measure>
    <time_frame>1 year after transplantation</time_frame>
    <description>Correlation of cccDNA rate with serologic and virologic status (AgHBe, HBV DNA, ...) at the moment of the transplantation and during post-transplantation period and HBV recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between cccDNA rate and virologic status</measure>
    <time_frame>1 year after transplantation</time_frame>
    <description>Correlation of cccDNA assay with serologic and virologic status (AgHBe, HBV DNA, ...) will be assessed at the moment of the transplantation and during post-transplantation period and HBV recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between cccDNA rate and patient's treatment</measure>
    <time_frame>1 year after transplantation</time_frame>
    <description>Correlation of cccDNA rate with patients' treatments will be assessed at the moment of the transplantation and during post-transplantation period and HBV recurrence</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>Patients with alcoholic or hepatitis C virus related disease</arm_group_label>
    <description>cccDNA assay on liver biopsy in patients with liver transplantation for alcoholic disease or hepatitis C virus (HCV) related disease, without contact with HBV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatitis B core antibody positive donors</arm_group_label>
    <description>cccDNA assay on liver biopsy in patients who receive liver from hepatitis B core antibody positive donors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBV patients</arm_group_label>
    <description>cccDNA assay on liver biopsy in patient with liver transplantation for chronic hepatitis B, with or without HBV replication</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cccDNA assay on liver biopsy</intervention_name>
    <description>cccDNA assay will be performed on liver biopsies at different times : During transplantation : Liver biopsy of explant and graft and virological biology Between M1 to M3 after transplantation : Liver biopsy between 1 to 3 months after transplantation M12 : Liver biopsy 12 months after transplantation</description>
    <arm_group_label>HBV patients</arm_group_label>
    <arm_group_label>Hepatitis B core antibody positive donors</arm_group_label>
    <arm_group_label>Patients with alcoholic or hepatitis C virus related disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with liver transplantation planned
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient registered on the national Organ Transplant Waiting List for liver
             transplantation

          -  Indication of transplantation :

          -  Alcoholic related disease without serum anti-hepatitis B core antibody (HBc) (less
             than 4 weeks) OR - HCV related disease without serum anti-HBc antibody (less than 4
             weeks) OR - Patients who sign consent for liver transplantation from hepatitis B core
             antibody positive donors OR - HBV related disease with positive serum HBs antigen
             (with or without HBV replication measured by polymerase chain reaction (PCR) within 6
             months prior transplantation)

          -  Signed consent form

          -  Patient with a social cover

          -  Patient not covered by any measure of legal protection

        Exclusion Criteria:

          -  Co-infection with HIV, hepatitis delta virus (HDV), HBV (for control arm), HCV (for
             Test arm) - Positive serology within the4 weeks before inclusion

          -  Patient covered by any measure of legal protection

          -  informed consent not signed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabien ZOULIM, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service d'Hépatologie, Hôpital Croix-Rousse, Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatologie, Hôpital de la Croix-Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 5, 2015</study_first_submitted>
  <study_first_submitted_qc>November 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2015</study_first_posted>
  <last_update_submitted>January 10, 2019</last_update_submitted>
  <last_update_submitted_qc>January 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver transplantation</keyword>
  <keyword>HBV</keyword>
  <keyword>cccDNA</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

